An Insider's Guide to Clinical Trials

An Insider's Guide to Clinical Trials

Volumn , Issue , 2011, Pages 1-296

  Meinert, Curtis L ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Clinical trials; Established treatments; Evidence based medicine; Media; Patients; Randomized trial; Treatments

Indexed keywords

EID: 84862497314     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1093/acprof:oso/9780199742967.001.0001     Document Type: Book

References (239)

1. Altman, Douglas G. 1991. Practical Statistics for Medical Research. London: Chapman & Hall. 16 chapters, 2 appendices, 611 pp.
2. Chow, Shein-Chung; Shao, Jun; Wang, Hanshang. 2003. Sample Size Calculations in Clinical Research. New York: Marcel Dekker. 12 chapters, 1 appendix, 372 pp.
3. Diggle, Peter J.; Heagerty, Patrick J.; Liang, Kung-Yee; Zeger, Scott L. 2002. Analysis of Longitudinal Data. New York: Oxford University Press. 14 chapters, 6 appendices, 379 pp.
4. Donner, Allan; Klar, Neil. 2000. Design and Analysis of Cluster Randomization Trials in Health Research. New York: Oxford University Press. 9 chapters; 178 pp.
5. Hill, Austin Bradford. 1955. Principles of Medical Statistics, 6th edition. New York:Oxford University Press, 1955. 314 pp.
6. Hill, Austin Bradford. 1962. Statistical Methods in Clinical and Preventive Medicine. New York: Oxford University Press. 610 pp.
7. Jennison, Christopher; Turnbull, Bruce W. 1999. Group Sequential Methods with Applications to Clinical Trials. London: Chapman & Hall. 19 chapters, 390 pp.
8. Petitti, Diana B. 2000. Meta-analysis, Decision Analysis and Cost-effectiveness Analysis: Methods for Quantitative Synthesis in Medicine, 2nd edition. New York: Oxford University Press. 17 chapters, 306 pp.
9. Shuster, Jonathan. 1990. CRC Handbook of Sample Size Guidelines for Clinical Trials. Boca Raton, FL: CRC Press. 3 chapters, 2 appendices, 854 pp.
10. van Belle, Gerald; Fisher, Lloyd D.; Heagerty, Patrick J.; Lumley, Thomas S. 2004. Biostatistics: A Methodology for the Health Sciences, 2nd edition. New York: John Wiley & Sons. 20 chapters, 1 appendix, 896 pp.
11. Armitage, Peter. 1975. Sequential Medical Trials, 2nd edition. New York: John Wiley & Sons. 194 pp.
12. Berger, Vance W. 2005. Selection Bias and Covariate Imbalances in Randomized Clinical Trials. New York: John Wiley & Sons. 8 chapters, 218 pp.
13. Buyse, Marc E.; Staquet, Maurice J.; Sylvester, Richard J. 1984. Cancer Clinical Trials: Methods and Practice. New York: Oxford University Press. 25 chapters, 481 pp.
14. Chow, Shein-Chung; Liu, Jen-Pei. 2003. Design and Analysis of Clinical Trials:Concepts and Methodologies, 2nd edition. New York: John Wiley & Sons. 15 chapters; 752 pp.
15. Ellenberg, Susan S.; Fleming, Thomas R.; DeMets, David L. 2002. Data Monitoring Committees in Clinical Trials: A Practical Perspective. New York: John Wiley & Sons. 10 chapters, 1 appendix, 191 pp.
16. Fleiss, Joseph L. 1986. Design and Analysis of Clinical Experiments. New York: John Wiley & Sons. 13 chapters, 1 appendix, 432 pp.
17. Friedman, Lawrence M.; Furberg, Curt D.; DeMets David L. 1998. Fundamentals of Clinical Trials, 3rd edition. New York: Springer. 19 chapters, 361 pp.
18. Hayes, Richard J.; Moulton, Lawrence H. 2009. Cluster Randomized Trials: A Practical Approach. Boca Raton, FL: Chapman & Hall/CRC Press. 338 pp.
19. Herson, Jay. 2009. Data and Safety Monitoring Committees in Clinical Trials. Boca Raton, FL: Chapman & Hall/CRC. 173 pp.
20. Meinert, Curtis L.; Tonascia, Susan. 1986. Clinical Trials: Design, Conduct, and Analysis. New York: Oxford University Press. 26 chapters, 9 appendices, 469 pp.
21. Piantadosi, Steven. 2005. Clinical Trials: A Methodologic Perspective, 2nd edition. New York: John Wiley & Sons. 22 chapters, 8 appendices, 687 pp.
22. Rosenberger, William F.; Lachin, John M. 2002. Randomization in Clinical Trials:Theory and Practice. New York: John Wiley & Sons. 15 chapters, 258 pp.
23. Senn, Stephen. 2002. Cross-over Trials in Clinical Research. New York: John Wiley & Sons. 10 chapters, 345 pp.
24. Smith, Peter G.; Morrow, Richard H. 1996. Field Trials of Health Interventions in Developing Countries: A Toolbox, 2nd edition. New York: Macmillian. 16 chapters, 362 pp.
25. Whitehead, John. 1997. The Design and Analysis of Sequential Clinical Trials, 2nd edition. New York: John Wiley & Sons. 9 chapters, 1 appendix, 328 pp.
26. Beauchamp, Tom L.; Faden, Ruth R.; Wallace, R.J. Jr.; Walters, L. 1982. Ethical Issues in Social Science Research. Baltimore: The Johns Hopkins University Press 19 chapters, 436 pp.
27. Faden, Ruth R.; Beauchamp, Tom L.; King, Nancy M. P. 1986. A History and Theory of Informed Consent. New York: Oxford University Press. 10 chapters; 392 pp.
28. Levine, Robert J. 1988. Ethics and Regulation of Clinical Research, 2nd edition.New Haven, CT: Yale University Press. 14 chapters, 5 appendices, 452 pp.
29. Silverman, William A. 1985. Human Experimentation: A Guided Step into the Unknown. New York: Oxford University Press. 12 chapters, 2 appendices, 204 pp.
30. Marks, Harry M. 1997. The Progress of Experiment: Science and Therapeutic Reform in the United Sates, 1900-1990. Cambridge: Cambridge University Press. 8 chapters; 258 pp.
31. Kolman, Josef; Meng, Paul; Scott, Graeme, eds. 1998. Good Clinical Practice:Standard Operating Procedures for Clinical Researchers. New York: John Wiley & Sons. 210 pp.
32. Egger, Matthias; Smith, George Davey; Altman, Douglas G., eds. 2001. Systematic Reviews in Health Care: Meta-analysis in Context. London: BMJ Publishing Group. 26 chapters, 487 pp.
33. Glasziou, Paul; Irwig, Les; Bain, Chris; Colditz, Graham. 2001. Systematic Reviews in Health Care: A Practical Guide. Cambridge: Cambridge University Press. 10 chapters, 2 appendices, 137 pp.
34. Whitehead, Annie. 2002. Meta-analysis of Controlled Clinical Trials. New York: John Wiley & Sons. 12 chapters, 1 appendix, 352 pp.
35. Hulley, Stephen B.; Cummings, Steven R.; Browner, Warren S.; Grady, Deborah; Hearst, Norman; Newman, Thomas B. 2001. Designing Clinical Research: An Epidemiological Approach, 2nd edition. Philadelphia: Lippincott Williams & Wilkins. 19 chapters, 336 pp.
36. Salsburg, David. 2001. The Lady Tasting Tea: How Statistics Revolutionized Science in the Twentieth Century. New York: WH Freeman. 29 chapters, 352 pp.
37. Brownson, Ross C.; Baker, Elizabeth A.; Leet, Terry L.; Gillespie, Kathleen N. 2003. Evidence-Based Public Health. New York: Oxford University Press. 9 chapters, 235 pp.
38. Woodin, Karen E. 2004. The CRC's Guide to Coordinating Clinical Research. Boston:Thomson Centerwatch. 12 chapters, 7 appendices, 411 pp.
39. Beers, Mark H.; Berkow, Robert, eds. 1999. The Merck Manual of Diagnosis and Therapy, 17th edition. New York: John Wiley & Sons. 2833 pp.
40. The Rand Corporation. 1955. A Million Random Digits with 100,000 Normal Deviates. New York: The Free Press (1955); Rand (2001). 628 pp.
41. U.S. DHHS, Office for Protection from Research Risks. Code of Federal Regulations, Title 45: Public Welfare, Part 46:Protection of Human Subjects. Revised 18 June 1991. Washington, DC: Office for Human Research Protections. 29 pp.
42. U.S. Food and Drug Administration. 2001, 2005. Code of Federal Regulations: Title 21 Food and Drugs. Online at http://www.access.gpo.gov/cgi-bin/cfrassemble.cgi? title=200121 http://www.accessdata.fda.gov/SCRIPs/cdrh/cfdocs/cfcfr/CRFSearch.cfm
43. Day, Simon. 2007. Dictionary for Clinical Trials, 2nd edition. New York: John Wiley & Sons 249 pp.
44. Dorland, W.A. Newman, ed. 2000. Dorland's Illustrated Medical Dictionary, 29th edition. New York: WB Saunders Company. 2088 pp.
45. Last, John M. 2001. A Dictionary of Epidemiology, 4th edition. New York: Oxford University Press. 196 pp.
46. Last, John M. 2007. A Dictionary of Public Health. New York: Oxford University Press. 407 pp.
47. Lynch, Jack, ed. 2002. Samuel Johnson's Dictionary: Selections from the 1755 Work that Defined the English Language. DelRay Beach, FL: Levenger Press. 646 pp.
48. Marriott, F.H.C. 1990. A Dictionary of Statistical Terms, 5th edition. New York:Longman Scientific and Technical. 223 pp.
49. Meinert, Curtis L. 1996. Clinical Trials Dictionary: Terminology and Usage Recommendations. Baltimore: Harbor Duvall Graphics. 363 pp.
50. Mish, Frederick C., editor-in-chief. 2003. Merriam-Webster's Collegiate Dictionary, 11th edition. New York: Merriam-Webster, Inc. 1664 pp.
51. Vogt, W. Paul. 1993. Dictionary of Statistics and Methodology. Thousand Oaks, CA: Sage Publications. 252 pp.
52. Winslade, Jeffery; Hutchinson, David. 1998. Dictionary of Clinical Research, 2nd edition. Surrey, UK: Brookwood Medical Publications. 115 pp.
53. Chicago Editorial Staff. 1993. The Chicago Manual of Style, 14th edition. Chicago:University of Chicago Press. 921 pp.
54. JAMA and Archive Journals. 2007. AMA Manual of Style: A Guide for Authors and Editors, 10th edition. New York:Oxford University Press. 1032 pp.
55. Strunk, William Jr.; White, E.B. 1999. The Elements of Style, 4th edition. New York:Longman. 105 pp.; latest edition of the original written by William Strunk Jr. and published in 1918.
56. Armitage, Peter; Colton, Theodore, eds. 2005. Encyclopedia of Biostatistics, 2nd edition. New York: John Wiley & Sons 8 vols., 6100 pp.
57. D'Agostino, Ralph B.; Sullivan, Lisa; Massaro, Joseph, editors-in-chief. 2008. Wiley Encyclopedia of Clinical Trials. New York: John Wiley & Sons. 4 vols., 2460 pp.
58. Codes and Guidelines Committee on Science, Engineering, and Public Policy (P. Griffiths, chair). 1995. On Being a Responsible Scientist, 2nd edition. New York: National Academy Press. 40 pp.
59. Council for International Organizations of Medical Sciences. 2002. International Ethical Guidelines for Biomedical Research Involving Human Subjects. Online at www.cioms.ch. 56 pp.
60. Hippocrates of Cos (460-370 BC). 1910. The Hippocratic Oath. Classical version. Boston: Harvard Classics. Volume 39.
61. International Committee of Medical Journal Editors. 2004. Clinical trial registration: A statement from the International Committee of Medical Journal Editors. JAMA 292:1363-1364.
62. International Committee of Medical Journal Editors. 2007. Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication. Online at www.icmje.org. 36 pp.
63. Moher, David; Schultz, Kenneth F.; Altman, Douglas G., for the CONSORT Group. 2001. Revised recommendations for improving the quality of reports of parallel group randomized trials. Lancet 357:1191-1194.
64. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research (KJ Ryan, Chair). 1979. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Washington, DC: U.S. Government Printing Office. No. 1983-381-132:3205.
65. NIH Office of Extramural Research. 6 March 1998. NIH Policy and Guidelines on the Inclusion of Children as Participants in Research Involving Human Subjects. Online at http://grants.nih.gov/grants/guide/notice-files/not98-024.html. 8 pp.
66. NIH Office of Extramural Research. 10 June 1998. NIH Policy for Data and Safety Monitoring. Online at http://grants.nih.gov/grants/guide/notice-files/NOT98-084.html. 4 pp.
67. NIH Office of Extramural Research. 1994. NIH Policy and Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research - Amended October 2001. Online at http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm. 10 pp.
68. NIH Office of Extramural Research. 1 March 2002. NIH Announces Draft Statement on Sharing Research Data. Online at http://grants.nih.gov/grants/guide/notice-files/NOTOD-02-035.html. 2 pp.
69. U.S. Department of Health and Human Services. 17 August 2000. Health insurance reform: Standards for electronic transactions: Announcement of designated standard maintenance organizations: Final rule and notice. Federal Register 65;160:50,312-50,372.
70. U.S. Nüremberg Military Tribunals. 1947. The Nüremberg Code. BMJ Vol. 313; 7 December 1996. 1 p.
71. World Medical Association General Assembly. 2004. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Online at www.wma.net. 5 pp.
72. University Group Diabetes Program Research Group. 1970. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes I. Design, methods, and baseline characteristics; II. Mortality results. Diabetes 19(Suppl 2):747-830.
73. Cornfield, J. 1971. The University Group Diabetes Program: A further statistical analysis of the mortality findings. JAMA 217:1676-1687.
74. Coronary Drug Project Research Group. 1973. The Coronary Drug Project: Design, methods, and baseline results. Circulation 47(Suppl I): I-1-I-50
75. Committee for the Assessment of Biometric Aspects of Controlled Trials of Hypoglycemic Agents. 1975. Report of the Committee for the Assessment of Biometric Aspects of Controlled Trials of Hypoglycemic Agents. JAMA 231:583-608.
76. Coronary Drug Project Research Group. 1983. The Coronary Drug Project:Methods and lessons of a multicenter clinical trial. Control Clin Trials 4:273-549.
77. Hypertension Prevention Trial Research Group. 1989. The Hypertension Prevention Trial (HPT): Design, methods, and baseline results. Control Clin Trials 10 (Suppl)1S-117S.
78. Beecher, H.K. 1966. Ethics and clinical research. N Engl J Med 274:1354-1360.
79. Tuskegee Syphilis Study Ad Hoc Advisory Panel (Broadus N. Butler, chair). 1973. Tuskegee Syphilis Study Ad Hoc Advisory Panel: Final Report. Washington, DC:United States Public Health Service. 47 pp. 47
80. Chalmers, T.C. 1975. Randomization of the first patient. Med Clin North Am 59:1035-1038.
81. Sackett, D.L., Gent, M. 1979. Controversy in counting and attributing events in clinical trials. N Engl J Med 301:1410-1412.
82. Coronary Drug Project Research Group. 1980. Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. N Engl J Med 303:1038-1041.
83. Freedman, B. 1987. Equipoise and the ethics of clinical research. N Engl J Med 317:141-145.
84. Yusuf, S., Wittes, J., Probstfield, J., Tyroler, H.A. 1991. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 266:93-98.
85. Committee on the Ethical and Legal Issues Relating to the Inclusion of Women in Clinical Studies (Ruth Faden and Daniel Federman, co-chairs). 1994. Women and Health Research: Ethical and Legal Issues of Including Women in Clinical Studies (in 2 volumes; 2nd volume Workshop and Commissioned Papers). New York:National Academy Press. Vol. 1., 271 pp.; vol. 2, 247 pp.
86. Institute of Medicine Committee to Review the Fialuridine (FIAU/FIAC) Clinical Trials(Morton Swartz, chair). 1995. Review of the Fialuridine (FIAU) Clinical Trials. New York: National Academy Press. 269 pp.
87. Parish, Peggy (illustrations by Fritz Siebel). 1963. Amelia Bedelia. New York:Harper Collins 64 pp.; children's book
88. Merriam, Eve (retold; illustrations by Trina Schart Hyman). 1968. Epaminondas. New York: Follett Publishing Co. 32 pp.; children's book.
89. Nash, Ogden (illustrations by James Marshall; 1991). 1963. The Adventures of Isabel. New York: Little Brown & Co. Children's book.
90. Piper, Watty (pen name for Mabel Bragg); illustrated by Lois Lenski. 1930.
91. The Little Engine That Could (aka The Pony Engine). New York: Platt & Munk; 1978 edition by Grosset & Dunlap. Children's book; 48 pp
92. Grimm, Jacob; Grimm, Wilhelm. 1812. Hansel and Gretel (in Grimms' Fairy Tales).
93. Author unknown (probably of Russian origin). Circa 1940 in U.S. The Little Red Hen.
94. Robert, Henry M., III; Evans, William J.; Honemann, Daniel H.; Balch, Thomas J. 2004. Robert's Rules of Order Newly Revised in Brief. Cambridge, MA: Da Capo Press. 20 chapters, 200 pp.
95. Huff, Darrell (illustrations by Irving Geis). 1954. How to Lie with Statistics. New York: W. W. Norton & Co. 142 pp.
96. Shaw, George Bernard. 1913. The Doctor's Dilemma.
97. Aesop. The Dog and His Shadow.
98. Aesop. The Hare and the Tortoise.
99. Baum, L. Frank. 1900. The Wonderful Wizard of Oz (also the Wizard of Oz). Chicago:George M Hill Co. (original publisher; many others since)
100. Bayan, Rick. 1994. Cynic's Dictionary. New York: Hearst Books. 190 pp.
101. Bierce, Ambrose. 1993 (reproduction of works published in 1911). The Devil's Dictionary. New York: Dover Publications, Inc. 145 pp
102. Truss, Lynne. 2003. Eats, Shoots & Leaves: The Zero Tolerance Approach to Punctuation. New York: Gotham Books. 209 pp.
103. Carroll, Robert T. 2003. The Skeptic's Dictionary: A Collection of Strange Beliefs, Amazing Deceptions, and Dangerous Delusions. New York: John Wiley & Sons. 456 pp.
104. Butler, Ellis Parker. 1905. Pigs is Pigs. New York: A. L. Burt Company. 37 pp.
105. Aesop. The Boy Who Cried Wolf (aka The Shepherd and the Wolf).
106. Author unknown. Stone Soup.
107. Numeroff, Laura Joffe (illustrated by Felicia Bond). 1985. If You Give a Mouse a Cookie. New York: HarperCollins.
108. ADAPT Research Group. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology. 2007;68:1800-1808.
109. ADAPT Research Group. Cardiovascular and cerebrovascular results from the randomized, controlled Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). PLoS Clin Trials. 2006; 1(7):e33.
110. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gøtzsche PC, Lang T: The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. Ann Intern Med. 2001; 134:663-694.
111. Amberson JB, Jr., McMahon BT, Pinner M. A clinical trial of sanocrysin in pulmonarytuberculosis. Am Rev Tuberc. 1931; 24:401-435.
112. American Bible Society. The Holy Bible: Old and New Testaments. King James Version (1611). New York: 1816.
113. Angell M. Industry-sponsored clinical research: A broken system. JAMA. 2008; 300:1069-1071.
114. Angell M. Investigators' responsibility for human subjects in developing countries. N Engl J Med. 2000; 342:967-969.
115. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324:71-86.
116. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994; 308:81-106.
117. Antman EM, Lau J, Kupeinick B, Mosteller F, Chalmers TC. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. JAMA. 1992; 268:240-248.
118. Bailey KR. Detecting fabrication of data in a multicenter collaborative animal study. Control Clin Trials. 1991; 12:741-752.
119. Baron J. The life of Edward Jenner: With illustrations of his doctrines and selections from his correspondence (book review). Br Foreign Med Rev. 1838; 6:477-497.
120. Bartolucci AA, Howard G. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin. Am J Cardiol. 2006; 98:746-750.
121. Beecher HK. Ethics and clinical research. N Engl J Med. 1966; 274:1354-1360.
122. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schultz KF, Simel D, Stroup DF. Improving the quality of reporting of randomized controlled trials: The CONSORT statement. JAMA. 1996; 276:637-639.
123. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: A sex-specific metaanalysis of randomized controlled trials. JAMA. 2006; 295:306-313.
124. Black's Law Dictionary. St. Paul, MN: West Publishing Company, 1990.
125. Box JF. RA Fisher and the design of experiments, 1922-1926. Am Statistician. 1980; 34:1-7.
126. Broad WJ.: U.S. to penalize heart researchers on fraudulent project at Harvard. New York Times. 16 February 1983.
127. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Pub Health. 1998; 88:1337-1342.
128. Canner PL. Aspirin in coronary heart disease: Comparison of six clinical trials. Isr J Med Sci. 1983; 19:413-423.
129. Childhood Asthma Management Program Research Group. The Childhood Asthma Management Program (CAMP): Design, rationale, and methods. Control Clin Trials. 1999; 20:91-120.
130. Collins JF, Garg R, Koon KT, Williford WO, Howell CL on behalf of DIG Investigators. The role of the data coordinating center in the IRB review and approval process: The DIG trial experience. Control Clin Trials. 2003; 24:306S-315S.
131. Colsky J. Clinical investigator: The clinical investigator and evaluation of new drugs. Am J Hosp Pharm. 1963; 20:517-519.
132. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997; 337:581-588.
133. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL, Jimenez E, O'Neill E, Bazin B, Delfraissy J-F, Culnane M, Coombs R, Elkins M, Moye J, Stratton P, Balsley J., for the Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994; 331:1173-1180.
134. Cornfield J. Recent methodological contributions to clinical trials. Am J Epidemiol. 1976; 104:408-421.
135. Cornfield J. Design of clinical trials. In Goldstein M, ed., Research Status of Spinal Manipulative Therapy, pp. 303-306. Monograph no. 15. Bethesda, MD: National Institute of Neurological and Communicative Disorders and Stroke, 1975.
136. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975; 231:360-381.
137. Coronary Drug Project Research Group. The Coronary Drug Project: Design, methods, and baseline results. Circulation. 1973; 47(Suppl I):I-1-I-50.
138. Couzin J. Drug testing: Massive trial of Celebrex seeks to settle safety concerns. Science. 2005; 310:1890-1891.
139. Creighton C. A history of epidemics in Britain: From the extinction of plague to the present time (vol. II). Cambridge: The University Press, 1894.
140. DeAngelis CD, Fontanarosa PB. Impugning the integrity of medical science: The adverse effects of industry influence. JAMA. 2008; 299:1833-1835.
141. DeAngelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, Kotzin S, Laine C, Marusic A, Overbeke AJPM, Schroeder TV, Sox HC, Van Der Weyden MB: Clinical trial registration: A statement from the International Committee of Medical Journal Editors. JAMA. 2004; 292:1363-1364.
142. Department of Health and Human Services. Public Health Services policies on research misconduct; 42 CFR Parts 50 and 93. Federal Register. 2005; 70:28370-28400.
143. Dieckmann WJ, Davis ME, Rynkiewicz LM, Pottinger RE. Does the administration of diethylstilbestrol during pregnancy have therapeutic value?. Am J Obst Gynecol. 1953; 66:1062-1081.
144. Diehl HS, Baker AB, Cowan DW. Cold vaccines: An evaluation based on a controlled study JAMA. 1938; 111:1168-1173.
145. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997; 336:525-533.
146. Drummond JC, Wilbraham A. The Englishman's food: A history of five centuries of English diet. London: Jonathan Cape, 1940.
147. Fenner F, Henderson DA, Arita I, Landyi ID. Smallpox and its eradication. Geneva: World Health Organization, 1988.
148. Fergusson D, Glass KC, Hutton B, Shapiro S. Randomized controlled trials of aprotinin in cardiac surgery: Could clinical equipoise have stopped the bleeding? Clin Trials. 2005; 2:218-232.
149. Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without radiation in the treatment of breast cancer. N Engl J Med. 1995; 333:1456-1451.
150. Fisher B, Bauer M, Margolese R, Poisson R, Pilch Y, Redmond C, Fisher E, Wolmark N, Deutsch M, Montague E, et al: Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med. 1985; 312:665-73.
151. Fisher RA. Statistical methods and scientific inference (3rd edition). New York: Hafner Press, Macmillan Publishing Co., 1973.
152. Fisher RA. The arrangement of field experiments. J Ministry Agric Great Britain. 1926; 33:503-513.
153. Fisher RA, MacKenzie WA. Studies in crop variation: II. The manurial response of different potato varieties. J Agric Sci. 1923; 13:311-320.
154. Food and Drug Administration. Procedural and interpretative regulations: Investigational use. Federal Register. January 8, 1963; 28:179-182.
155. Fost N, Levine RJ. The dysregulation of human subjects research. JAMA. 2008; 298:2196-2198.
156. Francis T, Korns RF, Voigt RB, Boisen M, Hemphill FM, Napier JA, Tolchinsky E. An evaluation of the 1954 poliomyelitis vaccine trial: Summary report. Am J Public Health. 1955; 45(Part II, May Suppl):1-51.
157. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987; 317:141-145.
158. Freedman LS, Simon R, Foulkes MA, Friedman L, Geller NL, Gordon DJ, Mowery R. Inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993-The perspective of NIH clinical trialists (with discussion and response). Control Clin Trials. 1995;16:277-312.
159. Freis ED. Historical development of antihypertensive treatment. In Laragh JH, Brenner BM, eds., Hypertension pathophysiology, diagnosis, and management, 2nd ed., Chapter 164, pp. 2741-2751. New York: Raven Press, 1995.
160. Glass GV. Primary, secondary and meta-analysis of research. Educational Researcher. 1976; 5:3-8.
161. Goodman SN. Toward evidence-based medical statistics. 1: The p value fallacy. Ann Intern Med. 1995; 130:995-1004.
162. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabito C, Sherman J, Bakaki P, Ducar C, Deseyve M, Emel L, Mirochnick M, Fowler MG, Mofenson L, Miotti P, Dransfield K, Bray D, Mmiro F, Jacksom JB: Intrapartum and neonatal single-dosenevirapine with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial. Lancet 1999; 354:795-802.
163. Hayes SN, Redberg RF. Dispelling the myths: Calling for sex-specific reporting of trials results. Mayo Clin Proc. 2008; 83:523-525.
164. Haygarth J. Of the imagination, as a cause and as a cure of disorders of the body: Exemplified by fictitious tractors, and epidemical convulsions. Bath: R Cruttwell, 1800.
165. Herbst AL, Scully RE. Adenocarcinoma of the vagina in adolescence. A report of 7 cases including 6 clear-cell carcinomas (so-called mesonephromas). Cancer. 1970; 25:745-757.
166. Hill AB. Statistical methods in clinical and preventive medicine. New York: Oxford University Press, 1962.
167. Huff D. How to lie with statistics. Illustrated, I Geis. New York: Norton, 1954.
168. Hypertension Detection and Follow-Up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-Up Program: I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA. 1979a; 242:2562-2571.
169. Hypertension Detection and Follow-up Program. Therapeutic control of blood pressure in the Hypertension Detection and Follow-up Program. Prev Med. 1979; 8:2-13.
170. Hypertension Prevention Trial Research Group, C Meinert, J Tonascia, S Tonasica, eds. The Hypertension Prevention Trial (HPT): Design, methods, and baseline results. Control Clin Trials. 1989; 10 (Suppl):1S-17S.
171. Ibarreta D, Swan SH: The DES story: Long-term consequences of prenatal exposure. In Harremoës P, Gee D, MacGarvin M, Stirling A, Keys J, Wynne B, Vaz SG, eds. Late lessons from early warnings: The precautionary principle 1896-2000. Chapter 8, pp. 84-91. Copenhagen: European Environment Agency, 2001.
172. International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. N Engl J Med. 1997; 336:309-315.
173. Jenner E. An inquiry into the causes and effects of the variolae vaccine. London: Sampson Low, 1798.
174. Johnson S. A dictionary of the English language. (2 vols.). Printed by W Strahan, for J and P Knapton; T and T Longman; C Hitch and L Hawes; A Millar; and R and J Dodsley, 1755.
175. Kassirer JP, Angell M. On authorship and acknowledgments. N Engl J Med. 1991; 325:1510-1512.
176. Kelsey FO. Government: The Kefauver-Harris Amendments and investigational drugs. Am J Hosp Pharm. 1963; 20:515-517.
177. Kluger J. Splendid solution: Jonas Salk and the conquest of polio. New York: Penguin Group (USA), 2005.
178. Last JM. A dictionary of epidemiology (4th edition). New York: Oxford University Press, 2001.
179. Levine RJ. Ethics and regulation of clinical research (2nd edition). New Haven: Yale University Press, 1988.
180. Lewis S, Clarke M.: Forest plots: Trying to see the wood and the trees. BMJ. 2001;322:1479-1480.
181. Lind J. A treatise of the scurvy (reprinted in Lind's Treatise on scurvy, edited by CP Stewart, D Guthrie, Edinburgh University Press, Edinburgh, 1953). Edinburgh: Sands, Murray, Cochran, 1753.
182. MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, et al. Systematic review: Comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008; 148:197-213.
183. Markel H. April 12, 1955 -Tommy Francis and the Salk Vaccine. N Engl J Med. 2005; 352:1408-1410.
184. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis: A Medical Research Council investigation. Br Med J. 1948; 2:769-782.
185. Medical Research Council. Clinical trials of new remedies (annotations). Lancet. 1931; 2:304.
186. Meinert C, Gilpin AK, Ünalp A, Dawson C. Gender representation in trials. Control Clin Trials. 2000; 21:462-475.
187. Meinert CL. Controlled Clinical Trials (the journal). Encyclopedia of biostatistics, vol. 1, pp. 929-931. Chichester, UK: John Wiley & Sons, 1998.
188. Meinert CL. Beyond CONSORT: Need for improved reporting standards for clinical trials. JAMA. 1998; 279:1487-1489.
189. Meinert CL. Masked monitoring in clinical trials-Blind stupidity?. N Engl J Med. 1998; 338:1381-1382.
190. Meinert CL. Clinical trials dictionary: Terminology and usage recommendations. Baltimore, MD: The Johns Hopkins Center for Clinical Trials, 1996. v
191. Meinert CL, Tonascia S. Clinical trials:Design, conduct, and analysis. New York: Oxford University Press, 1986. v, ix
192. Miller PD, Epstein S, Sedarati F, Reginster JY. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: Results from the head-to-head MOTION study. Curr Med Res Opin. 2008; 1:207-213.
193. Mills JL. Data torturing. N Engl J Med. 1993; 329:1196-1199.
194. Moher D. CONSORT: An evolving tool to help improve the quality of reports of randomized controlled trials. JAMA. 1998; 279:1489-1491.
195. Mount FW, Ferebee SH. Control study of comparative efficacy of isoniazid, streptomycin-isoniazid, and streptomycin-para-aminosalicylic acid in pulmonary tuberculosis therapy: II. Report on twenty-week observations on 390 patients with streptomycin-susceptible infections. Am Rev Tuberc. 1953a; 67:108-113.
196. Mount FW, Ferebee SH. Control study of comparative efficacy of isoniazid, streptomycin-isoniazid, and streptomycin-para-aminosalicylic acid in pulmonary tuberculosis therapy: III. Report on twenty-eight-week observations on 649 patients with streptomycin-susceptible infections. Am Rev Tuberc. 1953b; 67:539-543.
197. Mount FW, Ferebee SH. Control study of comparative efficacy of isoniazid, streptomycin-isoniazid, and streptomycin-para-aminosalicylic acid in pulmonary tuberculosis therapy: I. Report on twelve-week observations on 526 patients. Am Rev Tuberc. 1952; 66:632-635.
198. Multiple Risk Factor Intervention Trial Research Group. Statistical design considerations in the NHLI Multiple Risk Factor Intervention Trial (MRFIT). J Chronic Dis. 1977; 30:261-275.
199. Murray JAH, Bradley H, Craigie WA, Onion CT, eds. The Oxford English dictionary:A new English dictionary on historical principles (13 vols.). Oxford: Clarendon Press, 1970.
200. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: Ethical principles and guidelines for the protection of human subjects of research. No. 1983-381-132:3205. Washington, DC: US Government Printing Office, 1979.
201. U.S. Congress. National Institutes of Health Revitalization Act of1993. §131, Pub L No 103-43, 107 Stat 133 (codified at 42 USC §289a-2).
202. National Institutes of Health Department of Health and Human Services: NIH Guidelines on the inclusion of women and minorities as subjects in clinical research. Federal Register. March 28 1994; 59:14508-14513.
203. National Institutes of Health. NIH Almanac. Publ. no. 81-5. Bethesda, MD: Division of Public Information, 1981b.
204. Neaton JD, Bartsch GE, Broste SK, Cohen JD, Simon NM, for the MRFIT Research Group. A case of data alteration in the Multiple Risk Factor Intervention Trials (MRFIT). Control Clin Trials. 1991; 12:731-740.
205. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infraction and death from cardiovascular causes. N Engl J Med. 2007; 356:2457-2471.
206. O'Brien PC. Data and safety monitoring. In Encyclopedia of biostatistics, vol. 2, pp. 1058-1066. Chichester: John Wiley & Sons, 1998.
207. Office for Protection from Research Risks. Code of Federal Regulations, Title 45: Public Welfare, Part 46: Protection of Human Subjects. Bethesda, MD: Department of Health and Human Services, National Institutes of Health, revised 18 June 1991.
208. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y, for the Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: A randomized controlled trial. JAMA. 2008; 300:2134-2141.
209. Packard FR. Life and times of Ambroise Paré, 1510-1590. New York: Paul B Hoeber, 1921.
210. Patulin Clinical Trials Committee (of the Medical Research Council). Clinical trial of Patulin in the common cold. Lancet. 1944; 2:373-375.
211. Peto R, Collins R, Sackett D, Darbyshire J, Babiker A, Buyse M, Stewart H, Baum M, Goldhirsh A, Bonadonna G, Valagussa P, Rutqvist L, Elbourne D, Davies C, Dalesio O, Parmar M, Hill C, Clarke M, Gray R, Doll R: The trials of Dr. Bernard Fisher: A European perspective on an American episode. Control Clin Trials. 1997; 18:1-13.
212. Physicians' Health Study Research Group Steering Committee. Preliminary report: Findings from the aspirin component of the ongoing Physicians' Health Study. N Engl JMed. 1988; 318:262-264.
213. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips T, Lubin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW for the AFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006; 354:899-910.
214. Pruitt Jr. BA, Pruitt JH, Davis JH. Chapter 1, pp. 1-19. In Moore EE, Felficiano DV, Mattox KL, eds., Trauma (5th edition). New York: McGraw-Hill Professional, 2003.
215. Rennie D. Clinical trial misconduct. In Wiley encyclopedia of clinical trials. New York: John Wiley & Sons, 2007. Online at
216. Rennie D. How to report randomized controlled trials: The CONSORT statement. JAMA. 1996; 276:649.
217. Ries LAG. Childhood cancer mortality. In Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR, eds. Cancer incidence and survival among children and adolescents: United States SEER program: 1975-1995, pp. 165-170. SEER Monograph, Pub. No. 99-4649. Bethesda, MD: National Cancer Institute, 1999.
218. Rheumatic Fever Working Party of the Medical Research Council of Great Britain and the Subcommittee of Principal Investigators of the American Council of Rheumatic Fever and Congenital Heart Disease, American Heart Association. The evolution of rheumatic heart disease in children: Five year report of a cooperative clinical trial of ACTH, cortisone and aspirin. Circulation. 1960; 22:503-515.
219. Robinson D, Shettles L. The use of diethylstilbestrol in threatened abortion. Am J Obstet Gynecol. 1952; 63:1330-1333.
220. Savulescu J, Chalmers I, Blunt J. Are research ethics committees behaving unethically? Some suggestions for improving performance and accountability. Br Med J. 1996; 313:1390-1393.
221. Shuster E. Fifty years later: The significance of the Nüremberg Code. N Engl J Med. 1997; 337:1436-1440.
222. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiological data. Prev Med. 1991; 20:47-63.
223. Titus SL, Rhoades LJ. Repairing research integrity. Nature. 2008; 453:980-982.
224. Thomas KJ, MacPherson H, Trope L, Brazier J, Fitter M, Campbell MJ, Roman M, Walters SJ, Nicholl J: Randomised controlled trial of a short course of traditionalacupuncture compared with usual care for persistent non-specific low back pain. BMJ. 2006; 333:623.
225. Tucker WB. The evolution of the cooperative studies in the chemotherapy of tuberculosis of the Veterans Administration and Armed Forces of the USA: An account of the evolving education of the physician in clinical pharmacology. Adv Tuberc Res. 1960; 10:1-68.
226. United States Congress (103rd; 1st session). NIH Revitalization Act of 1993, 42 USC § 131 (1993); Clinical Research Equity Regarding Women and Minorities; Part I: Women and Minorities as Subjects in Clinical Research. 1993.
227. United States Congress (87th): Drug Amendments of 1962, Public Law 87-781, S 1522. Washington, DC, Oct 10, 1962.
228. United States Supreme Court. Forsham et al. versus Harris, Secretary of Health, Education and Welfare, et al. Certiorari to the United States Court of Appeals for the District of Columbia Circuit. No. 78-1118, argued Oct 31, 1979, decided March 3, 1980.
229. University Group Diabetes Program Research Group. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: VIII. Evaluation of insulin therapy: Final report. Diabetes. 1982; 31(Suppl 5):1-81.
230. University Group Diabetes Program Research Group. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: VII. Mortality and selected nonfatal events with insulin treatment. JAMA. 1978;240:37-42.
231. University Group Diabetes Program Research Group. A Study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes:V. Evaluation of Phenformin therapy. Diabetes. 1975; 24 (Suppl 1):65-184.
232. University Group Diabetes Program Research Group. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: I. Design, methods, and baseline characteristics. Diabetes. 1970; 19(Suppl 2):747-783. ix
233. University Group Diabetes Program Research Group. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: II. Mortality results. Diabetes 1970; 19(Suppl 2):785-830.
234. U.S. Preventive Services Task Force. Aspirin for the Primary Prevention ofCardiovascular Events: Recommendation and Rationale. Ann Inter Med. 2002; 136:157-160.
235. Vuthipongse P, Bhadrakom C, Chaisilwattana P, Roongpisuthipong A, Chalermchokcharoenkit A Chearskul S, Wanprapa N, Chokephaibulkit K, Tuchipda M, Wasi C, Chuachoowong R, Siriwasin W, Chinayon P, Asavapiriyanont S, Chotpitayasunondh T, Waranawat N, Sangtaweesin V, Horpaopan S, Queen Sirikit: Administration of zidovudine during late pregnancy and delivery to prevent perinatal HIV transmission -Thailand, 1996-1998. MMWR. 1998; 47:151-153.
236. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P: Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008 Jan 23.
237. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA. 2002; 288:321-333.
238. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA. 1991; 266:93-98.
239. Zarin DA, Ide NC, Tse T, Harlan WR, West JC, Lindberg DA. Issues in the registration of clinical trials. JAMA. 2007; 297:2112-2120.